Dyne Therapeutics (NASDAQ:DYN) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Dyne Therapeutics (NASDAQ:DYN) from a sell rating to a strong sell rating in a research report released on Saturday.

Several other equities analysts also recently commented on the company. TD Cowen initiated coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Evercore set a $33.00 price target on Dyne Therapeutics in a report on Friday, May 15th. Morgan Stanley lowered their price objective on Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating for the company in a research note on Friday. Royal Bank Of Canada raised their price objective on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a report on Thursday, July 30th. Finally, Cantor Fitzgerald started coverage on shares of Dyne Therapeutics in a research report on Thursday, July 23rd. They set an “overweight” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.42.

Dyne Therapeutics Stock Performance

NASDAQ DYN opened at $25.24 on Friday. The firm’s fifty day moving average price is $21.39 and its two-hundred day moving average price is $18.93. The stock has a market cap of $4.71 billion, a PE ratio of -7.58 and a beta of 1.06. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. Dyne Therapeutics has a fifty-two week low of $9.89 and a fifty-two week high of $26.26.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.33). On average, equities analysts expect that Dyne Therapeutics will post -3.28 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the sale, the chief financial officer directly owned 121,563 shares in the company, valued at approximately $2,476,238.31. This trade represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jason P. Rhodes sold 297,211 shares of Dyne Therapeutics stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the completion of the sale, the director directly owned 2,962 shares of the company’s stock, valued at approximately $68,896.12. This trade represents a 99.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders purchased 9,000 shares of company stock valued at $156,800 and sold 1,642,038 shares valued at $35,898,156. Insiders own 9.46% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Hedge funds have recently bought and sold shares of the business. Hilton Head Capital Partners LLC acquired a new position in shares of Dyne Therapeutics during the first quarter valued at about $26,000. Strs Ohio bought a new position in Dyne Therapeutics in the 4th quarter valued at about $51,000. Aster Capital Management DIFC Ltd acquired a new position in Dyne Therapeutics during the 4th quarter valued at about $84,000. Steward Partners Investment Advisory LLC boosted its stake in Dyne Therapeutics by 102.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after purchasing an additional 2,465 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its holdings in Dyne Therapeutics by 275.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after purchasing an additional 7,697 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.